Jia Wang1, Xutong Li2, Dongfeng Zhang3. 1. Department of Epidemiology and Health Statistics, The Medical College of Qingdao University, No. 38 Dengzhou Road, Qingdao, 266021, China. 2. Department of Oncology, Second Affiliated Hospital, The Medical College of Qingdao University, Qingdao, China. 3. Department of Epidemiology and Health Statistics, The Medical College of Qingdao University, No. 38 Dengzhou Road, Qingdao, 266021, China. zhangdf1961@126.com.
Abstract
PURPOSE: Results from epidemiologic studies on coffee consumption and the risk of cutaneous melanoma are inconsistent. We conducted a meta-analysis to assess the associations between the consumption of total coffee, caffeinated coffee and decaffeinated coffee and the risk of cutaneous melanoma, respectively. METHODS: A literature search was performed in PubMed, Web of Science and EMBASE for relevant articles published up to August 2015. Pooled relative risks (RRs) with 95 % confidence intervals (CIs) were calculated with a random-effects model. Dose-response relationship was assessed by restricted cubic spline. RESULTS: Twelve studies involving 832,956 participants for total coffee consumption, 5 studies involving 717,151 participants for caffeinated coffee consumption and 6 studies involving 718,231 participants for decaffeinated coffee consumption were included in this meta-analysis. Compared with the lowest level of consumption, the pooled RRs were 0.80 (95 % CI 0.69-0.93, I (2) = 53.5 %), 0.85 (95 % CI 0.71-1.01, I (2) = 65.0 %) and 0.92 (95 % CI 0.81-1.05, I (2) = 0.0 %) for the consumption of total coffee, caffeinated coffee and decaffeinated coffee, respectively. In subgroup analysis by study design, the pooled RRs in cohort studies and case-control studies were 0.83 (95 % CI 0.72-0.97) and 0.74 (95 % CI 0.51-1.07) for total coffee consumption, respectively. Dose-response analysis suggested cutaneous melanoma risk decreased by 3 % [0.97 (0.93-1.00)] and 4 % [0.96 (0.92-1.01)] for 1 cup/day increment of total coffee and caffeinated coffee consumption, respectively. CONCLUSIONS: This meta-analysis suggests that coffee consumption may reduce the risk of cutaneous melanoma.
PURPOSE: Results from epidemiologic studies on coffee consumption and the risk of cutaneous melanoma are inconsistent. We conducted a meta-analysis to assess the associations between the consumption of total coffee, caffeinated coffee and decaffeinated coffee and the risk of cutaneous melanoma, respectively. METHODS: A literature search was performed in PubMed, Web of Science and EMBASE for relevant articles published up to August 2015. Pooled relative risks (RRs) with 95 % confidence intervals (CIs) were calculated with a random-effects model. Dose-response relationship was assessed by restricted cubic spline. RESULTS: Twelve studies involving 832,956 participants for total coffee consumption, 5 studies involving 717,151 participants for caffeinated coffee consumption and 6 studies involving 718,231 participants for decaffeinated coffee consumption were included in this meta-analysis. Compared with the lowest level of consumption, the pooled RRs were 0.80 (95 % CI 0.69-0.93, I (2) = 53.5 %), 0.85 (95 % CI 0.71-1.01, I (2) = 65.0 %) and 0.92 (95 % CI 0.81-1.05, I (2) = 0.0 %) for the consumption of total coffee, caffeinated coffee and decaffeinated coffee, respectively. In subgroup analysis by study design, the pooled RRs in cohort studies and case-control studies were 0.83 (95 % CI 0.72-0.97) and 0.74 (95 % CI 0.51-1.07) for total coffee consumption, respectively. Dose-response analysis suggested cutaneous melanoma risk decreased by 3 % [0.97 (0.93-1.00)] and 4 % [0.96 (0.92-1.01)] for 1 cup/day increment of total coffee and caffeinated coffee consumption, respectively. CONCLUSIONS: This meta-analysis suggests that coffee consumption may reduce the risk of cutaneous melanoma.
Authors: Lena Maria Nilsson; Ingegerd Johansson; Per Lenner; Bernt Lindahl; Bethany Van Guelpen Journal: Cancer Causes Control Date: 2010-05-30 Impact factor: 2.506
Authors: A-C Goulet; Janine G Einsphar; David S Alberts; Anthony Beas; Cynthia Burk; Achyut Bhattacharyya; Jerry Bangert; Janet M Harmon; Hideji Fujiwara; Alane Koki; Mark A Nelson Journal: Cancer Biol Ther Date: 2003 Nov-Dec Impact factor: 4.742
Authors: Song-Yi Park; Neal D Freedman; Christopher A Haiman; Loïc Le Marchand; Lynne R Wilkens; Veronica Wendy Setiawan Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-05-18 Impact factor: 4.254